Nurix Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $26
Nurix Therapeutics Analyst Ratings
Nurix Therapeutics Analyst Ratings
Nurix Therapeutics Gains Buy Rating Amid Strong Clinical Advances for CLL Drug NX-5948
Nurix Therapeutics Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)
Nurix Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)
Analysts Offer Insights on Healthcare Companies: Evogene (EVGN), Edwards Lifesciences (EW) and Nurix Therapeutics (NRIX)
RBC Lifts Price Target on Nurix Therapeutics to $23 From $22, Keeps Outperform Rating, Speculative Risk Qualifier
Nurix Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Nurix Therapeutics (NRIX)
Analysts Conflicted on These Healthcare Names: Conmed (CNMD), AbbVie (ABBV) and Nurix Therapeutics (NRIX)
Nurix Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Madrigal Pharmaceuticals (MDGL)
Nurix Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and DaVita (DVA)
Nurix Therapeutics Earns 'Buy' Rating on Strong Partnerships and Revenue Potential
Nurix Therapeutics Analyst Ratings